A Medical Device Daily

Wound Management Technologies (WMT; Fort Worth, Texas) reported it has closed on its acquisition of Resorbable Orthopedics a private company with patented technologies including a resorbable bone wax and a delivery system for orthopedic bone void fillers, among others

Resorbable Orthopedics has become a wholly owned subsidiary of WMT in a stock transaction.

Scott Haire, CEO of WMT, said, "This highly significant acquisition adds complementary orthopedic biomaterials products to our existing CellerateRx wound care products. WMT, through two subsidiaries, is participating in one of the fastest growing medical markets worldwide. The total global biomaterial market is currently $28 billion and is expected to exceed $58 billion in the next five years. The orthopedic biomaterials market is nearly $10 billion alone, driven by improved patient benefits, a shorter FDA approval cycle and an aging population ever more aware of biomaterial benefits."

In other dealmaking activity:

• Thermo Fisher Scientific (Waltham, Massachusetts) reported that it has completed its previously reported acquisition of B.R.A.H.M.S. (Hennigsdorf, Germany) for €330 million ($470 million). B.R.A.H.M.S. generated 2008 revenues of €75 million ($105 million), and is expected to be accretive to adjusted earnings per share in 2010. Thermo Fisher will integrate B.R.A.H.M.S. into its Analytical Technologies Segment, and plans to use the firm's former headquarters in Hennigsdorf, Germany, as the European Center of Excellence for its clinical diagnostics business.

Best known today for its flagship test, Procalcitonin (PCT), B.R.A.H.M.S is a provider of specialty in-vitro diagnostic tests based on patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

• Cortec Group (New York) a private equity firm which invests in middle-market manufacturing, distribution, healthcare and proprietary services businesses, reported that on Sept. 30 that its affiliate, Cortec Group Fund IV, L.P., in partnership with management, acquired a majority interest in Katena Products (Denville, New Jersey). Terms of the transaction were not disclosed.

Katena, is producer and supplier of precision manufactured micro instruments for ophthalmic surgeries of the anterior segment of the eye (i.e., cataracts, corneal transplants, LASIK, glaucoma). The company's products are sold globally to hospitals, ambulatory surgery centers and individual ophthalmic surgeons, under the Katena brand name.